You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
翰宇藥業(300199.SZ):注射用胸腺法新、注射用更昔洛韋被列入防控藥品目錄
格隆匯 02-04 20:00

格隆匯2月4日丨翰宇藥業(300199.SZ)公佈,公司股票於2020年1月23日、2月3日、2月4日連續三個交易日漲幅累計達11.69%。

近期,新型冠狀病毒性肺炎在全國範圍內出現,疫情引起廣泛關注;公司主打產品注射用胸腺法新被上海、天津等地區列入防控藥品清單,注射用胸腺法新可通過促進T淋巴細胞成熟,增加抗原或絲裂原激活後T細胞分泌的干擾素和白介素等淋巴因子水平、增加T細胞表面淋巴因子受體水平,增強機體抗病毒、抗細菌能力,公司同類藥物注射用胸腺五肽曾在抗擊“非典”中發揮了積極作用;公司的注射用更昔洛韋也被廣東省衞生健康委員會列入防控藥品目錄,可用於抗病毒治療;相應產品的市場需求有望進一步擴大。公司積極響應黨中央和習近平總書記重要指示,把人民羣眾生命安全和身體健康放在首位,堅決支援全國抗疫工作部署,全力以赴安排趕產,積極履行企業社會責任,根據疫情進展,組織公司生產的藥品第一時間捐贈抗疫前線,盡最大能力滿足疫情及人民羣眾的用藥需求。

公司全資子公司甘肅成紀生物藥業有限公司生產的小兒對乙酰氨基酚片和複方氨酚烷胺片等可有效緩解患者發熱、頭痛、四肢痠痛、打噴嚏、咽痛等症狀;維生素C咀嚼片和維生素EC顆粒可用於免疫力低下人羣的日常保健,增強抵抗力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account